KRT7

Across TCGA pan-cancer cohorts, KRT7 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated KRT7 data layer compared with 26 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher KRT7 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated KRT7 expression acts as an unfavorable survival marker, although some lineages such as GBM show a favorable association.

PDAC, GBM, and CCRCC are the cancer types where KRT7 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Median	All	0.399	0.743	<.001	87	view →
GBM	OS	Tertile	All	0.968	0.726	<.001	10	view →
CCRCC	OS	Quartile	III,IV	0.047	0.977	.017	6	view →
LUAD	DFS	Quartile	III,IV	0.206	0.698	.012	3	view →
LSCC	DFS	Median	All	0.913	0.954	.024	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

KRT7–PDAC (OS)

Open the PDAC breakdown →